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Abstract 
 
     Research on the neurobiology of the kynurenine pathway has suffered years of relative 
obscurity because tryptophan degradation, and its involvement in both physiology and major 
brain diseases, was viewed almost exclusively through the lens of the well-established 
metabolite serotonin. With increasing recognition that kynurenine and its metabolites can 
affect and even control a variety of classic neurotransmitter systems directly and indirectly, 
interest is expanding rapidly. Moreover, kynurenine pathway metabolism itself is modulated 
in conditions such as infection and stress, which are known to induce major changes in well-
being and behaviour, so that kynurenines may be instrumental in the etiology of psychiatric 
and neurological disorders. It is therefore likely that the near future will not only witness the 
discovery of additional physiological and pathological roles for brain kynurenines, but also 
ever-increasing interest in drug development based on these roles. In particular, targeting 
the kynurenine pathway with new specific agents may make it possible to prevent disease by 
appropriate pharmacological or genetic manipulations.  
     The following overview focuses on areas of kynurenine research which are either 
controversial, of major potential therapeutic interest, or just beginning to receive the degree 
of attention which will clarify their relevance to neurobiology and medicine. It also highlights 
technical issues so that investigators entering the field, and new research initiatives, are not 
misdirected by inappropriate experimental approaches or incorrect interpretations at this 
time of skyrocketing interest in the subject matter. 
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The early days 
     The kynurenine pathway, which is initiated by the oxidative metabolism of tryptophan, has 
been studied in some detail since the early part of the twentieth century. It was originally 
viewed primarily as the synthetic route to nicotinamide and hence nicotinamide adenine 
dinucleotide (NAD+), a crucial co-factor for a wide range of enzymes. The kynurenine 
pathway formed an intriguing link between the dietary availability of vitamin B6 and 
tryptophan metabolism (see Badawy, 2016) since many of the major enzymes in the 
cascade were B6-dependent, and B6 deficiency was usefully characterised by the increased 
excretion of xanthurenic acid in the urine (Bender et al., 1990). No specific neurobiological 
activity was demonstrated for kynurenine and its catabolic products until (Lapin, 1978) 
showed that several tryptophan metabolites could produce convulsions when injected 
directly into the brain. A number of publications had earlier reported abnormal concentrations 
of kynurenine in various brain disorders, although those results were interpreted in terms of 
their effects on tryptophan and serotonin levels (Curzon, 1969; Dewhurst, 1970; Wood et al., 
1978). 
     By the mid-1970s, reports began to appear in support of the notion that glutamate, a 
simple amino acid, was likely to be an excitatory neurotransmitter in the central nervous 
system (CNS) (Stone, 1973, 1976). Furthermore, the use of selective antagonists to block 
synaptic excitation suggested the existence of more than one subtype of glutamate 
receptors (Davies et al., 1979; McLennan, 1983). It was during a screen of several dozen 
newly synthesised compounds that agonist activity was detected in one of them. This 
compound, pyridine-2,3-dicarboxylic acid, also named quinolinic acid and long known as a 
major component of the kynurenine pathway, produced an increase in neuronal firing rate in 
the rat cerebral cortex (Perkins and Stone, 1983b; Stone and Perkins, 1981). Neuronal 
excitation was blocked by 2-amino-5-phosphonopentanoic acid (AP5), a compound reported 
earlier the same year to block those glutamate receptors that were selectively sensitive to N-
methyl-D-aspartate (NMDA) (Davies et al., 1981; Perkins et al., 1982; Perkins et al., 1981). 
Thus, quinolinic acid was identified as an endogenous, selective agonist at NMDA receptors 
(Stone and Perkins, 1981). 
    NMDA was already known to produce axon-sparing, “excitotoxic” loss of neurons in the 
CNS (Schwarcz et al., 1978), leading to the suggestion that an overexcitation of NMDA 
receptors might play a key role in the aetiology of neurodegenerative disorders such as 
Alzheimer's disease or Huntington’s disease (HD), as well as epilepsy and stroke (Schwarcz 
and Meldrum, 1985). In line with its ability to act as a NMDA receptor agonist, quinolinic acid 
was also found to cause excitotoxic neuronal lesions, which could be prevented by the 
selective NMDA receptor antagonist 2-amino-7-phosphonoheptanoic acid (AP7) (Foster et 
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al., 1983). As a result, the focus of attention for understanding the biological roles of 
quinolinic acid in the CNS became centered on disorders associated with neuronal damage 
and degeneration (Lee et al., 2016; Lovelace et al., 2016).  
     By testing other compounds in the kynurenine pathway, a second metabolite, kynurenic 
acid, was later characterised as a glutamate receptor antagonist, blocking the actions of 
glutamate, NMDA and quinolinic acid, as well as related agonists thought to define other 
glutamate receptor subtypes, namely quisqualic acid [acting at what are now known as α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] and kainic acid 
(Perkins and Stone, 1982; Stone and Darlington, 2002). In line with the demonstration that 
NMDA receptor antagonists prevent excitotoxicity and seizures (Croucher et al., 1982; 
Schwarcz et al., 1982), kynurenic acid was then soon shown to possess pronounced 
neuroprotective and anticonvulsant effects (Foster et al., 1984).  
     Around the same time, interest developed in the biological function of one of the initial 
enzymes in the kynurenine pathway, indoleamine-2,3-dioxygenase (IDO), which converts 
tryptophan to kynurenine. Pfefferkorn (Pfefferkorn, 1984) observed that IDO was activated 
by interferon-ɣ during the immune response to infection, inhibiting the detrimental effects of 
the infectious agent. This insight triggered a long-running debate on whether the mechanism 
of the anti-infective effect was caused by the depletion of tryptophan or by the accumulation 
of kynurenine and its downstream metabolites (Badawy et al., 2016). 
     Mostly as a result of these early reports, interest in the kynurenine pathway has grown 
progressively and at an increasing rate, with over 15,000 articles published to date. The 
kynurenine field now encompasses a wide range of studies in physiology, pharmacology and 
immunology, with potential clinical relevance in areas as seemingly disparate as neurological 
and psychiatric diseases, diabetes and cancer (Strasser et al., 2016). In this review, we shall 
limit ourselves to highlighting a few selected areas of investigation in which there exist 
important yet largely unresolved questions with regard to basic biology and implications for 
brain pathology. Subsequent papers in this issue of “Neuropharmacology” address individual 
topics in more detail to provide a flavour of the growing depth and breadth of interest in the 
kynurenine pathway. 
  
Kynurenine pathway metabolism:  some unsettled basic issues 
     One important problem facing neurobiologists is that the traditionally accepted scheme of 
tryptophan metabolism via kynurenine (Figure 1) does not always agree with experimental 
findings, raising fundamental questions with regard to the origin and disposition of 
components of the pathway. For example, the concentration of quinolinic acid in the brain 
does not decline as predicted after pharmacological inhibition or genomic elimination of 
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kynurenine 3-monooxygenase (KMO). Thus, despite large increases in the brain levels of 
kynurenic acid (10-100-fold), indicating a shift of pathway metabolism towards the formation 
of the neuroprotective agent, administration of a selective KMO inhibitor does not affect brain 
quinolinic acid levels at all (Clark et al., 2005), and even the complete genomic deletion of 
KMO reduces brain quinolinic acid levels only by around 20% (Giorgini et al., 2013). At the 
same time, brain levels of anthranilic acid and picolinic acid, two pathway metabolites which 
have received relatively little attention so far, increase several-fold in these experimental 
situations.   
     Two conditions in which these phenomena may be pathophysiologically significant are 
cerebral malaria and trypanosomiasis. Mice treated with strains of the malaria parasite 
(Plasmodium), which induce a cellular and cerebral pathology closely resembling that seen 
in humans, develop progressive cerebral inflammation and behavioural impairments, and die 
within 7 days (Clark et al., 2005). When treated with the KMO inhibitor Ro 61-8048, however, 
the animals, which show 100-fold increases in the levels of kynurenic acid and anthranilic 
acid in the brain, survive for at least 21 days. This raises the possibility that not only 
kynurenic acid but also anthranilic acid may have beneficial effects in pathological situations 
that are associated with an inflammatory state. Perhaps it is no coincidence that the 
molecular structures of many non-steroidal anti-inflammatory and analgesic drugs currently 
available are built around the anthranilate nucleus (Mohamed Eissa et al., 2012; Sharma et 
al., 2002). 
     Many questions remain. If kynurenines are key players in the inflammatory process, are 
they drivers of functional changes or merely biologically inert bystanders? Are changes in 
the levels of the metabolites a direct consequence of immune regulations of individual 
kynurenine pathway enzymes or secondary reactions to entirely different stimuli? What are 
the differences between acute and chronic inflammation, given that chronic conditions are 
often associated with compensatory metabolic adjustments? 
     Another issue of fundamental relevance to neuroscientists pertains to the cellular 
localization of kynurenine pathway enzymes and their products in the mammalian brain. With 
exceptions (Guillemin et al., 2007), most studies indicate that brain kynurenines are 
synthesized or degraded in glial cells rather than in neurons under both normal and 
pathological conditions. Thus, neuronal lesions, which are typically accompanied by 
astrogliosis and microglial proliferation, are mostly associated with elevated enzyme 
activities and higher, rather than lower, levels of pathway metabolites (Ceresoli et al., 1997; 
Guidetti et al., 1995). The generally accepted view holds that the main branch of the 
cascade, leading to 3-hydroxykynurenine, 3-hydroxyanthranilic acid, quinolinic acid and 
beyond, is normally contained in microglial cells whereas kynurenic acid is formed in 
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astrocytes in a second, competing branch of the pathway (Figure 1). This conclusion is 
largely based on in vitro studies using individual cell types in culture (Chen et al., 2011; 
Chiarugi et al., 2001; Heyes et al., 1997; Kiss et al., 2003; Kocki et al., 2002) and, 
unfortunately to a far lesser extent, immunocytochemical analyses with antibodies directed 
against purified enzymes or against metabolites themselves (Guidetti et al., 2007; Lehrmann 
et al., 2001). Specifically, in the absence of anti-KMO antibodies that can be used for 
unambiguous microscopic localization of the enzyme, evidence for a microglial localization of 
this pivotal pathway enzyme rests mostly on ex vivo studies (Guillemin et al., 2005; Parrott 
and O'Connor, 2015). Notably, however, though the concept of a physical segregation of the 
two arms of the pathway in the brain is intuitively attractive, the dynamics of cerebral 
kynurenine pathway metabolism change substantially under abnormal conditions (Hoshi et 
al., 2009; Parrott and O'Connor, 2015; Saito et al., 1993; Wu et al., 2013).  It follows that the 
cellular localisation of individual pathway enzymes, as well as the functional relationship 
between the two pathway branches, in the brain ought to be carefully assessed and 
interpreted in future studies.     
     A third major challenge for neuroscientists is related to the fact that the influence of 
peripheral kynurenines on brain function is still not fully understood. Although circulating 
tryptophan as well as some pathway metabolites (including the pivotal kynurenine and 3-
hydroxykynurenine) can enter the brain quite easily under physiological conditions (Fukui et 
al., 1991; Pardridge, 1998), important open questions abound. For example, since most 
challenge studies so far have only examined the central effects of acute fluctuations in 
plasma kynurenines, far too little is known about possible qualitative and quantitative 
adaptations of the blood-brain barrier to persistent up- or downregulation of kynurenine 
pathway metabolism in the periphery. What about the effects of pathological changes in 
blood-brain barrier permeability, causing abnormalities in endothelial cells and capillary 
function in specific parts of the brain (Owe-Young et al., 2008)? With regard to possible 
neuropharmacological applications, can targeted manipulations of the large neutral amino 
acid transporter, which normally mediates the brain uptake of blood-derived kynurenines 
(Pardridge, 1983, 1998), be used to influence cerebral pathway metabolism and function?    
 
Molecular sites of action 
     Over the last decade, a plethora of newly identified molecular sites and receptors have 
been suggested to mediate the biological effects of the various metabolites of the kynurenine 
pathway. These novel molecular targets may exist on neurons or various non-neuronal brain 
cells, or on immune cells in the periphery, presenting significant impediments for the 
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unambiguous interpretation of data involving pharmacological or genetic manipulations of 
the pathway. 
     While quinolinic acid is certainly an agonist at NMDA receptors, various subtypes of 
NMDA receptors and subunit combinations are differentially sensitive to the metabolite. In 
particular, quinolinic acid is relatively selective for NMDA receptors in the neocortex and 
hippocampus, with much weaker activity in the cerebellum and spinal cord (Perkins and 
Stone, 1983a, b), correlating with the weakness of quinolinate’s activity at NR2C subunits 
(de Carvalho et al., 1996; Monaghan and Beaton, 1991) and the low expression of NR2C 
and NR2B subunits in the cerebellum (Scherzer et al., 1997; Wang et al., 1995). Quinolinic 
acid can also generate reactive oxygen species, which may contribute to neuronal damage 
under pathological conditions (Santamaria et al., 2001). 
     In addition it is becoming clear that quinolinic acid contributes to many areas of 
neurobiology and related systems. Many of these topics have been admirably reviewed 
elsewhere (Guillemin 2012) but include important interactions with the immune system. Pro-
inflammatory mediators such as TNFα can promote quinolinic acid production (Guillemin et 
al. 2001) and interleukin-1β potentiates quinolinate excitotoxicity (Stone and Behan 2007) 
while suppressors of inflammation such as interleukin-4 inhibit it (Musso et al. 1994). A 
number of indole-derived compounds as well as structurally related agents can suppress 
quinolinic acid production by inhibiting TDO (Botting 1995).  
     Although the direct effects of quinolinic acid are mediated primarily on NMDA receptors, 
quinolinic acid can also promote the release and inhibit the re-uptake of glutamate (Tavares 
et al. 2002) potentially facilitating the activation of kainate and AMPA receptors as well as 
metabotropic glutamate receptors. Furthermore, quinolinic acid has some intracellular 
actions which are probably independent of membrane receptors involvement. For example, 
quinolinic acid increases the phosphorylation of several proteins including tau filament 
proteins implicated in Alzheimer's disease (Rahman et al., 2009; Pierozan et al. 2010). 
     Kynurenic acid is well established as an antagonist at all ionotropic glutamate receptor 
subtypes, with greatest potency blocking the obligatory glycine-B co-agonist site on NMDA 
receptors (Birch et al., 1988a, b). An argument against the physiological relevance of this 
action is that inhibition is only seen at concentrations that are substantially higher than those 
normally found endogenously in the CNS. However, upon efflux (whether active or passive) 
from neurons or glia, concentrations in the immediately surrounding tissue could easily reach 
levels similar to, or greater than, those known to be pharmacologically active and sufficient 
to directly affect NMDA receptor-mediated synaptic transmission. By the time kynurenic acid 
has diffused away from its sites of production, diluted by several orders of magnitude in the 
extracellular fluid and eventually the cerebrospinal fluid (CSF), its levels will have fallen 
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substantially. Extracellular concentrations of kynurenic acid will also be reduced by active 
removal from the brain (Moroni et al., 1988) and cellular re-uptake (Uwai et al., 2012). 
Together, these factors make it difficult to rely on measurements of absolute concentrations 
of kynurenic acid and other pathway metabolites in tissue, microdialysate, CSF or plasma 
when attempting to assess target engagement in the context of physiological effects, 
pathological symptoms, and treatment.  
     Understanding the mechanism of action of kynurenic acid is especially difficult since the 
compound appears to have several biological targets in addition to glutamate receptors. One 
argument against a preferential role of NMDA receptor inhibition is that 7-chlorokynurenic 
acid, which blocks the glycine-B co-agonist site with approximately 20-fold higher affinity 
than kynurenic acid itself (Leeson et al., 1991), does not duplicate the actions of kynurenic 
acid in several experimental paradigms in vitro and in vivo (Beggiato et al., 2013; Beggiato et 
al., 2014; Hilmas et al., 2001). On the other hand, 7-chlorokynurenic acid itself may not act 
as a selective glycine-B antagonist in vivo (Lehmann et al., 1993) and even potentiates 
NMDA receptor activation in human embryonic kidney cells (Smothers and Woodward, 
2007). Differential affinity of 7-chlorokynurenic acid at glycine binding sites of various NMDA 
receptor subtypes (Nilsson et al., 2007; O'Shea et al., 1991), possible brain region-specific 
effects (Linderholm et al., 2007), and the ability of kynurenic acid to modulate extracellular 
glutamate levels in the brain (see Schwarcz, 2016, for review), further complicate 
interpretation.  
      Another potential target is the α7 homomeric nicotinic receptor (Hilmas et al., 2001) 
though this site, too, has not yet been unequivocally validated. Thus, several independent 
studies have failed to reproduce the original observations (see Albuquerque and Schwarcz, 
2013, for discussion; Arnaiz-Cot et al., 2008; Dobelis et al., 2012; Mok et al., 2009). Other 
investigators used pharmacological tools such as galantamine, an allosteric enhancer of α7 
nicotinic receptor function that acts as an agonist at a site that overlaps with the site targeted 
by kynurenic acid (Lopes et al., 2007). But the drug also inhibits the activity of cholinesterase 
and other esterases at higher concentrations (Darvesh et al., 2003; Nordberg and Svensson, 
1998), possibly limiting its ability to provide definitive proof for the involvement of α7 
receptors in the actions of kynurenic acid. Moreover, galantamine blocks some potassium 
channels (Vicente et al., 2010; Vigneault et al., 2012), which may be sufficient to explain its 
facilitatory effect on neuronal transmission and its apparent reversal of the effects of 
kynurenate. 
     To add to these complexities, kynurenic acid can also activate the G-protein coupled 
receptor GPR35 (Stone et al., 2013; Wang et al., 2006). Although found primarily on immune 
cells and in the gastrointestinal tract, this protein does occur in the CNS where it is located 
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on astrocytes (Moroni et al., 2012) and has been linked to nociceptive phenomena and 
neurotransmission in the hippocampus (Alkondon et al., 2015). Here, too, the extent to which 
this activity is relevant physiologically or under pathological conditions remains unclear, 
requiring further in-depth evaluation. Finally, kynurenic acid is an agonist at the aryl 
hydrocarbon receptor (AHR) (DiNatale et al., 2010), a xenobiotic-sensing receptor that 
promotes the metabolism of environmental toxins and functions in immune-regulation 
(Stephens et al., 2013). This site is present on tumour cells and cells of the immune system, 
sparking considerable interest in the role of kynurenines in the initiation and development of 
cancers (Bessede et al., 2014; Opitz et al., 2011). Implications for neurobiology, including 
neuropharmacology, are not unlikely but have not been explored so far.   
     One additional aspect that makes the kynurenine pathway increasingly interesting is that 
kynurenine itself, as well as its metabolites 3-hydroxykynurenine and 3-hydroxyanthranilic 
acid, are biologically active. Like kynurenic acid, kynurenine is an AHR agonist with unknown 
downstream effects (Opitz et al., 2011). 3-hydroxykynurenine and 3-hydroxyanthranilic acid 
are both redox active and may function to regulate and maintain the oxidative status of 
tissues in order to prevent cell damage by reactive oxygen species (Chobot et al., 2015; 
Gonzalez-Esquivel et al., 2016; Shibata et al., 2014). In addition, 3-hydroxyanthranilic acid 
also has distinct actions within the immune system. Target molecules which may function as 
3-hydroxyanthranilic acid receptors have been demonstrated on dendritic cells and a range 
of T cells including Th1 cells and FoxP3+ Treg cells (Xie et al., 2015). While the precise 
nature of the effects mediated through these sites is still unclear, the overall effect of 3-
hydroxyanthranilic acid seems to be anti-inflammatory (Krause et al., 2011). This concept is 
consistent with studies showing profound changes in 3-hydroxyanthranilic acid 
concentrations in inflammatory disorders and their normalisation on treatment (Forrest et al., 
2006), especially when considered in terms of the ratio with anthranilic acid (Darlington et 
al., 2010). 
     Clarification of the differential roles and relevance of these various target sites is clearly a 
pressing problem and should be pursued with high urgency. Ideally, newly produced 
selective agonists and antagonists can soon be used as tools to achieve this objective in the 
laboratory. These experimental agents might then also constitute lead compounds for the 
development of new drugs which might be suitable in a range of clinical conditions involving 
kynurenine pathway metabolites. 
 
Technical and methodological considerations 
     In studies of the role of kynurenines in the CNS, the majority of useful information has 
been gleaned from work on in vivo models or acutely prepared tissue slices, though studies 
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with freshly dissociated cells (neurons, astrocytes and microglia) have also provided relevant 
information (Guillemin et al., 2007; Guillemin et al., 2005). In contrast, cell culture systems 
have proved less valuable and are often controversial. This is a reflection of the fact that cell 
lines – even those that are purportedly from the same original stock and are labelled as the 
same cell type – are quite heterogeneous and show progressively changing characteristics 
with repeated passages (Nugoli et al., 2003). This problem has received most attention in 
the cancer field, where some of the most widely used cell lines are now known to exhibit 
substantially different growth patterns and molecular signatures between suppliers and 
research laboratories (Nugoli et al., 2003; Xie et al., 2012), but often also muddies research 
of CNS kynurenines. Thus, though observations of intracellular biochemical events or 
effector targets (receptors, ion channels) of kynurenines in neuronal and glial cultures 
continue to be useful, great caution must be exercised when extrapolating such data with 
regard to functional interactions between various cell types. The continuous biochemical 
dialogue between neurons and glia, and between intra- and extracellular compartments of 
these cells, as well as the presence in the CNS of a considerable number of small molecule 
regulators of kynurenine pathway metabolism (Chen et al., 2011; Guillemin et al., 2007; 
Guillemin et al., 2005), present far greater challenges to experimental reproducibility and 
interpretation than studies using dissociated cells of peripheral origin, such as hepatocytes 
or myocytes. 
      Apart from an increased attention to the role of individual cell populations, it is not difficult 
to predict that the development of new experimental tools, too, will contribute greatly to 
solving the many open questions of kynurenine neurobiology. This includes approaches 
involving the genes of specific pathway enzymes, such as the generation of knockout 
animals, the search for informative spontaneous mutations and single nucleotide 
polymorphisms (Aoyama et al., 2006; Holtze et al., 2012; Wonodi et al., 2014), and gene 
silencing methodologies (Vidal et al., 2015).  Moreover, conditional knockouts or knockdown 
models of each of the kynurenine pathway enzymes are expected to clarify the functional 
dynamics of pathway metabolism in the CNS in the near future. 
     The value of the new information obtained from genetic observations and manipulations 
will be further enhanced by the use of human or small animal imaging techniques, which can 
be used to visualize and quantify enzyme expression or activity non-invasively in vivo. This 
will require the design and radioactive labelling of appropriate specific ligands, and may 
include agonists/activators and antagonists/inhibitors of receptors, enzymes and other 
proteins that are known to define and determine the functions of kynurenines in the brain. 
Among many other conceivable applications, successful development of these tools will 
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make it possible to discriminate between splice variants of proteins or between enzyme 
isoforms – for example the four subtypes of kynurenine aminotransferase (Han et al., 2010).  
 
The gut-brain axis 
     As investigators pay increasing attention to the relationship between the gastrointestinal 
microbiome and the brain, with thousands of bacterial species under constant flux and 
variation with changes in the diet and nutritional status of the host (Bauer et al., 2016; 
Ghaisas et al., 2016; Ojeda et al., 2016), it is important to explore the potential role of 
microbes in the metabolism and function of the kynurenine pathway. Humans and most 
other mammals do not have the ability to synthesise tryptophan, which is therefore 
considered an “essential” amino acid. In contrast, tryptophan is readily neosynthesised by 
most plants and bacteria (Barends et al., 2008; Marinoni et al., 2008; Turski et al., 2011).  
  Interestingly, bacteria also utilize other mechanisms which account for the formation and 
degradation, respectively, of neuroactive kynurenines. For example, bacteria can neo-
synthesize quinolinic acid (Marinoni et al., 2008; Reichmann et al., 2015; Sakuraba et al., 
2005; Saunders et al., 2008), and unique prokaryotic enzymes can degrade kynurenic acid 
(Taniuchi and Hayaishi, 1963). Bacterial neosynthesis of quinolinic acid begins with the 
condensation of iminoaspartate with dihydroxyacetone, and the latter compound also inhibits 
α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) (Garavaglia et al., 
2009). Normally, ACMS cyclises non-enzymatically to quinolinic acid, but is converted to 
picolinic acid in the presence of ACMSD. Inhibition of ACMSD by bacterial dihydroxyacetone 
will therefore increase the synthesis of quinolinic acid. Another source of quinolinic acid may 
be anthranilic acid (first converted to 3-hydroxyanthranilic acid by anthranilate oxidase; Liu et 
al., 2010), and bacteria can also produce quinolinic acid non-enzymatically (Cleaves and 
Miller, 2001). These bacterial processes may play a part in – still ill-defined – biological roles 
of endogenous quinolinic acid in the mammalian brain. We predict that more detailed 
information on these alternative processes involving the gut microbiome will be essential to 
understand fully the dynamics of cerebral tryptophan metabolism and, in particular, the 
balance between quinolinic acid and kynurenic acid production and function in the brain. In 
other words, it is tempting to speculate that microbially-regulated tryptophan and 
kynurenines significantly influence CNS function and dysfunction in mammals (Kennedy et 
al., 2016; O'Mahony et al., 2015). 
 
CNS development  
     The nature and possible functional role of kynurenines in the developing brain has begun 
to receive increased attention in recent years. In rodents, the fetal brain contains remarkably 
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high concentrations of neuroactive kynurenines compared to the adult brain (Ceresoli-
Borroni and Schwarcz, 2000), and a similar observation has been made with regard to 
prenatal cerebral kynurenic acid levels in non-human primates (Beal et al., 1992). As the 
brain content of all these metabolites falls off precipitously immediately after birth, the high 
fetal brain levels likely originate either from the maternal circulation or from the placenta. 
Still, various scenarios may account for the high prenatal levels of brain kynurenines. 
Possibilities include, for example, relatively unimpeded transport of kynurenine and/or 3-
hydroxykynurenine from the maternal blood or the placenta to the fetal brain and, 
subsequently, robust production of downstream metabolites due to high activities of 
kynurenine pathway enzymes in the fetal brain. Alternatively or in addition, and in contrast to 
their very low ability to penetrate the blood-brain barrier in adulthood (Fukui et al., 1991), the 
polar compounds kynurenic acid and quinolinic acid, derived from the mother or the 
placenta, may be able to enter the fetal brain relatively freely. These fundamental principles 
of kynurenine neurobiology are readily testable experimentally. Detailed knowledge is 
overdue and will significantly impact our thinking about the possible physiological role of the 
high brain levels of kynurenines during the prenatal period.          
     The term ‘neuro-developmental diseases’ has been coined to refer to disorders that 
appear in late childhood or adulthood but are caused by abnormal early development of the 
CNS. In principle, early developmental impairments may be genetic in origin or caused by 
adverse external influences including bacterial or viral infections, exposure to environmental 
or dietary toxins, or experience of stressful situations (O'Farrell and Harkin, 2016). It is now 
recognised that these factors directly affect the kynurenine pathway in at least three general 
ways. Firstly, infections induce an immune response which raises the production of several 
cytokines such as interferon-γ, interleukin-1β and tumour necrosis factor-α (TNF-α). These 
as well as other pro-inflammatory cytokines in turn induce tryptophan 2,3-dioxygenase 
(TDO) and KMO and therefore increase pathway flux (Pemberton et al. 1997; Smith et al., 
2001) 
    Secondly, psychological stress causes increased synthesis and secretion of adrenal 
glucocorticoid hormones, which in turn affect kynurenines both in the periphery and in the 
brain (Laugeray et al., 2010). Thirdly, some naturally occurring compounds such as the 
brassinins, found in a number of vegetables, can inhibit IDO and thus reduce activity along 
the entire kynurenine pathway (Banerjee et al., 2008; Gaspari et al., 2006). 
     The fundamental importance of these links between kynurenine pathway metabolism and 
brain development is particularly apparent when considering the influence of environmental 
factors on the embryonic brain. Infection by viruses, bacteria or parasites is associated with 
the activation of Toll-Like Receptors (TLRs), especially TLR3 and TLR4, which can be 
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activated experimentally by agents such as bacterial lipopolysaccharide (LPS) or the viral-
mimetic double-stranded RNA poly(inosinic:cytidylic) acid (poly I:C). TLR activation results in 
stimulation of the kynurenine pathway (Asp et al., 2010; Clarke et al., 2012; Opitz et al., 
2009; Suh et al., 2007; Wang et al., 2011), so that any infection contracted during pregnancy 
is likely to be accompanied by increased production of kynurenines. This effect may depend 
on the age at which TLR activation occurs (Khalil et al., 2013). In light of the fact that 
changes in kynurenine metabolism affect brain development (Forrest et al., 2013a; Forrest et 
al., 2013b), with consequences which persist into adulthood (Forrest et al., 2013b; 
Notarangelo and Pocivavsek, 2016; Pisar et al., 2014), any infection during the very early 
stages of brain development may therefore result in CNS dysfunction, or increased 
susceptibility to dysfunction, later in life. For example, in rats, perinatal administration of 
influenza virus stimulates cerebral kynurenine pathway metabolism acutely, resulting in 
impaired sensorimotor function in adulthood (Asp et al., 2010). As human brain development 
continues for several years after birth (Ballesteros et al., 1993; Gogtay et al., 2004; Jernigan 
et al., 2011), spanning times when children are exposed to a range of harmful environmental 
influences, these studies suggest that the vulnerable period may, in fact, extend into the 
early years of childhood in humans. Activation of the kynurenine pathway could certainly 
explain the emergence of psychiatric disorders in people born to mothers exposed to a 
range of infectious organisms including Toxoplasma gondii,rubella, influenza and 
cytomegalovirus (Hunt et al., 2016; Libbey et al., 2005; Torrey et al., 2007; Torrey et al., 
2012; Yolken and Torrey, 2008) or to persistent stressful events in utero and beyond.   
     In view of the central role of glutamatergic mechanisms in brain development (Metzger, 
2010),  impaired glutamate function in the brain could constitute a common molecular 
mechanism linking perinatal imbalance of kynurenines to subsequent vulnerability and 
pathology. Indeed, prenatal interventions affecting kynurenine pathway metabolism affect 
the expression of glutamate receptor subunits (Forrest et al., 2013a; Forrest et al., 2013b), 
and abnormalities of glutamate-related cognitive performance are seen after repeated early 
stress  (Tse et al., 2011; Yuen et al., 2012). It is therefore not difficult to predict that the 
nature and effects of imbalanced glutamatergic neurotransmission following abnormal 
kynurenine pathway metabolism during brain development will become a major focus of 
investigation for many years to come. 
   Finally, although not directly related to CNS function, it is important to note the crucial role 
played by IDO and its regulation at the earliest stages of implantation, embryogenesis, 
maternal immune tolerance and the maternal-fetal balance. These factors and interactions, 
(reviewed by Badawy et al. 2016; see Stone 2016) are important influences on the initiation 
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and maintenance of a successful pregnancy and hence a complete and normal CNS 
development.  
 
CNS diseases: Huntington’s disease as an example 
     As described and discussed in several articles in this issue of “Neuropharmacology”, 
dysfunctions in kynurenine pathway metabolism have been tentatively linked to the etiology 
of a considerable number of CNS diseases. Paradigmatically, we are limiting our comments 
here to the potential role of kynurenines in the pathogenesis of the neurodegenerative 
disorder HD, which is inherited in an autosomal dominant fashion. As noted earlier, this 
hypothesis originated more than three decades ago with the demonstration that an 
intrastriatal injection of quinolinic acid in rats duplicates an array of neuropathological, 
neurochemical and behavioural features that are characteristic of the human disease 
(Schwarcz et al., 2010). Subsequent post-mortem studies in humans revealed a significantly 
increased activity of 3-hydroxyanthranilic acid dioxygenase, the immediate biosynthetic 
enzyme of quinolinic acid, in brain tissue of HD victims compared to controls (Schwarcz et 
al., 1988), and found substantially elevated levels of quinolinic acid in cortex and striatum of 
patients who had died in the early stages of the disease (Guidetti et al., 2004). In apparent 
further support of a pathophysiologically significant connection to kynurenines, the same HD 
samples also showed greatly increased levels of 3-hydroxykynurenine, which generates 
highly reactive free radicals and thereby potentiates the neurotoxic effects of quinolinic acid 
(Guidetti and Schwarcz, 1999).  
     The fact that HD is well understood from a genetic perspective offers new opportunities 
for assessing the role of the kynurenine pathway in pathology. The protein huntingtin, which 
holds the key to the disorder, is located on the short arm of chromosome 4 and contains a 
terminal poly-glutamine repeat chain, which is normally up to about 35 residues in length. If 
the chain length exceeds 40 residues, individuals exhibit HD symptoms. The severity of 
symptoms and disease progression increase with increasing numbers of glutamine repeats 
on mutant huntingtin (Forrest et al., 2010). This linkage allows investigators to directly test 
the involvement of molecular entities such as kynurenines in the disease process, and 
supportive data have been obtained in several genetic HD mouse models (Schwarcz et al., 
2010). In a study in humans, HD patients and their healthy relatives (≤ 35 glutamine repeats) 
were classified into four groups based on symptom severity – no, few, moderate or severe. 
Samples of saliva were then collected for the determination of the number of poly-glutamine 
repeats, and blood was taken for the analysis of tryptophan and kynurenine in the serum. 
The results revealed highly significant correlations between the kynurenine/tryptophan ratio, 
i.e. the activity of the initial oxidative step in the kynurenine pathway, and both symptom 
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severity and – crucially – the length of the poly-glutamine expansion in mutant huntingtin 
(Forrest et al., 2010). These results naturally raise a host of interesting questions and are 
especially intriguing on principal grounds, supporting the hypothesis that a genetically 
determined increase in kynurenine pathway activity may indeed contribute to the symptoms 
and disease progression in HD. More generally, this comprehensive approach, combining 
genetic assays and systematic clinical evaluations with chemical analyses in blood or other 
readily accessible body fluids, represents a promising model for the study of other CNS 
disorders with suspected etiological connections to kynurenines.   
 
Future directions   
     As demonstrated above using selected examples, studies of kynurenine neurobiology 
have begun to diversify into many areas of interest. Additional recent discoveries illustrate 
the unpredictability of the field and at the same time highlight entirely new, translationally 
relevant research trajectories. Thus, work by Ruas and collaborators recently revealed that 
the skeletal muscle enzyme PGC1α1 modulates kynurenine metabolism and at the same 
time causes resilience to depression caused by chronic mild stress (Agudelo et al., 2014). 
Specifically, the authors report that the enzyme, when induced by exercise, up-regulates 
kynurenine aminotransferase activity and reduces circulating kynurenine levels, and propose 
that this effect is critical for the well-established antidepressant consequences of exercise in 
animals and humans. Although the study does not clarify the mechanism(s) by which brain 
kynurenines might be involved, this intriguing study implies that the treatment of depression 
might be possible by pharmacological modulation of PGC activity – in effect postulating an 
“exercise pill” based on modulating kynurenine pathway metabolism.  
     Another recent study, describing the effects of nutritional restriction on tryptophan 
degradation along the kynurenine pathway, may also be relevant for the pathophysiology of 
depression since altered appetite is a common symptom of the disease. Thus, in the 
nematode C. elegans, reduced intake of tryptophan was found to lower the levels of 
kynurenic acid, allowing increased activation of NMDA receptors. This, in turn, resulted in 
higher activity of neuropeptide Y-containing cells, which secondarily promoted feeding 
behaviour by stimulating serotonergic neurons (Lemieux et al., 2015). This intriguing 
neurochemical cascade is consistent with studies in mammals, which show that feeding is 
promoted by the activation of serotonin 2C receptors (Voigt and Fink, 2015). Indeed over-
activation of these receptors may contribute to abnormally high appetite and, ultimately, 
obesity. In line with these findings and observations, it will be interesting to explore whether 
modification of kynurenine pathway metabolism, and specifically a reduction of kynurenic 
acid synthesis, holds promise as an intervention to achieve appetite reduction in humans. 
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     Another noteworthy study in C. elegans demonstrated that a loss of TDO2 activity 
reduces neuronal death associated with three potent neurotoxic peptides: α-synuclein, 
amyloid-β and extended poly-glutamine peptides (van der Goot and Nollen, 2013; van der 
Goot et al., 2012). These findings imply that TDO2 may normally facilitate the toxicity of the 
peptides, possibly involving a distinct site on the TDO2 molecule which normally regulates 
protein metabolism. Intriguingly, a reduction in TDO2 expression also results in a 
prolongation of lifespan in the worms (see Badawy, 2016; Oxenkrug et al., 2011). If these 
remarkable effects can be duplicated in mammals, efforts to decipher the underlying 
molecular mechanism(s) will certainly multiply. One of the many questions to be addressed 
is whether similarly impressive effects can be achieved by down-regulation of IDO and 
TDO1, which are highly conserved orthologs of TDO2. 
     Another topic that deserves careful study and is beginning to receive increasing attention 
is the link between kynurenines and stem cell biology. Human and mouse mesenchymal and 
neural stem cells express the entire kynurenine pathway (Croitoru-Lamoury et al., 2011), 
and pluripotent adult progenitor cells have IDO-dependent immunomodulatory properties, 
implicating kynurenine, and possibly its downstream metabolites, as effectors (Jacobs et al., 
2013). Of the many open questions, clarification of the mechanisms by which kynurenines 
influence stem cell proliferation and differentiation may be of greatest interest to cell 
biologists and other pre-clinical researchers. However, a thorough understanding of these 
effects will also increase the likelihood of success of stem cell-based therapies in a variety of 
infectious and inflammatory diseases affecting the brain. 
     In the context of depressive illness, there is a pressing need to clarify whether 
kynurenines are unequivocally involved in pathophysiology. The existence of this 
connection, specifically a role of an immune-stimulated increase in cerebral quinolinic acid 
levels in pathogenesis, has been repeatedly proposed, but the hypothesis has not been fully 
confirmed so far (Clark et al., 2016). Notably, changes in kynurenine pathway metabolism 
may be preferentially, or even exclusively, seen in patients with suicidal intent (Bradley et al., 
2015; Bryleva and Brundin, 2016; Sublette et al., 2011). Here, the levels of kynurenic acid 
were significantly reduced in patients and correlated with the severity of depressive 
symptoms. Conceivably, therefore, the disease may be causally related to an imbalance 
between quinolinic acid and kynurenic acid in the brain, with a relative abundance of the 
former leading to enhanced NMDA receptor function and symptoms of depression. It is 
interesting to speculate that the primary biochemical defect in depressive states may lie in 
the generation of kynurenic acid, leaving increased levels of kynurenine to be converted to 
quinolinic acid, whereas in schizophrenia the primary cause is more likely to be dysfunction 
of KMO (Holtze et al. 2012; Wonodi et al. 2011, 2014) which interrupts the formation of 
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quinolinic acid and diverts kynurenine towards kynurenic acid. Of note, this scenario would 
not only explain the efficacy of NMDA antagonists as rapidly acting antidepressants (Coyle 
and Laws, 2015; Drewniany et al., 2015; Machado-Vieira et al., 2009) but raises the 
possibility that interventions causing an elevation of brain kynurenic acid levels may provide 
clinical benefits in the disease.  
     New genetic information, too, will provide valuable insights into the roles of kynurenines 
in physiological processes and, in particular, in pathological phenomena affecting the CNS. 
The presence and remarkable conservation of most elements of the kynurenine pathway in 
organisms ranging from prokaryotes to humans, together with the recent development of 
highly sophisticated and precise molecular tools to study and manipulate DNA or RNA, will 
undoubtedly generate novel – and testable – biological hypotheses. One of the most 
interesting experimental targets in this regard is the pivotal pathway enzyme KMO. In fact, 
specific genetic features such as distinct single nucleotide polymorphisms in Kmo in patients 
with schizophrenia (see above), and reduced levels of the mRNA for KMO in prefrontal 
cortex tissue from patients with bipolar disorder with psychotic features (Lavebratt et al., 
2014), have been identified in recent years. Interestingly, the latter study revealed, 
specifically, an association between a KMO Arg(452) allele and manic psychosis, and 
between this allele and raised levels of kynurenic acid in these patients. All these findings 
await verification in larger cohorts and, subsequently, careful evaluation of functional 
consequences.     
     Finally, we assert that thorough investigations of the relationship between kynurenines 
and other (neuro)biologically active tryptophan metabolites are overdue and of fundamental 
importance. Although functionally significant interactions between kynurenine pathway 
metabolites and other prominent tryptophan products such as serotonin and melatonin are 
not unlikely, far too little is known in this respect. In the brain as in the periphery, cross-talk 
of the various catabolic branches of tryptophan, perhaps also involving additional 
metabolites such as tryptamine, will surely turn out to be complex, and elucidation will be 
challenging. Uni- or bi-directional influences could well vary with brain region, life stage, 
circadian rhythm and physiological requirements, and may differ among species. Most likely, 
pathological events will need to be assessed individually in this respect, though 
commonalities may exist in maladies with shared features, for example excitotoxic 
neurodegeneration or abnormalities of the immune system.    
 
Summary and final comments 
     Research on the neurobiology of the kynurenine pathway has suffered years of relative 
obscurity because tryptophan degradation, and its involvement in both physiology and major 
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brain diseases such as depression, schizophrenia (Erhardt et al., 2016) and 
neurodegenerative disorders, was viewed almost exclusively through the lens of the well-
established metabolite serotonin (and to some extent melatonin). With increasing recognition 
that kynurenine and its metabolites can affect and even control a variety of classic 
neurotransmitter systems directly and indirectly, interest is expanding rapidly. Moreover, as 
evidence accumulates that, in turn, kynurenine pathway metabolism itself is modulated in 
conditions such as infection and stress, which are known to induce major changes in well-
being and behaviour, it is also becoming apparent that kynurenines may be instrumental in 
the etiology of psychiatric and neurological disorders (Fujigaki et al., 2016; Hunt et al., 2016). 
It is therefore likely that the near future will not only witness the discovery of additional 
physiological and pathological roles for brain kynurenines, but also ever-increasing interest 
in drug development based on these roles. In particular, targeting the kynurenine pathway 
with new specific agents may make it possible to prevent disease by appropriate 
pharmacological manipulations (Dounay et al., 2012; Dounay et al., 2015; Jayawickrama et 
al., 2015; Stone and Darlington, 2013; Wu et al., 2014; Zwilling et al., 2011). Knowledge of 
the kynurenine pathway will be central to one of the cardinal achievements of medical 
research – averting disease rather than treating its symptoms. 
     We focused here on areas of kynurenine research which are either controversial, of major 
potential therapeutic interest, or just beginning to receive the degree of attention which will 
clarify their relevance to neurobiology and medicine. We also highlighted technical issues 
which require careful consideration in study design, experimental approaches and data 
evaluation. Although several of these concerns are not unique to the kynurenine pathway, 
we feel that it is important that investigators entering the field, and new research initiatives, 
are not misdirected by misleading results or incorrect interpretations at this time of 
skyrocketing interest in the subject matter. 
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Figure legend   
 
Figure 1: The kynurenine pathway of tryptophan degradation 
 
 
 
 
 
